A heart-wrenching story unfolds as a Guernsey family faces an unimaginable dilemma: selling their possessions to afford life-saving medication for their baby.
The Cost of Survival
Kiely Luscombe and her partner are desperate, feeling lost and abandoned by the system. Their nine-month-old son, Arnold, battles dysmotility and hypermotility, disorders that wreak havoc on his digestive system. The pain is excruciating, and the only relief comes from a specialized medication, Mebeverine.
But here's where it gets controversial: this medication, crucial for Arnold's well-being, is not covered by Guernsey's prescription funding. The family was shocked to discover the price - a staggering £312.70 per bottle, with each bottle lasting a mere month.
Luscombe shares her anguish: "I feel lost. We've tried everything, and now we're at a dead end. It's as if no one can help us."
Teena Bhogal, the Chief Pharmacist, assures support, stating, "We want families to know they're not alone. Clinicians can always reach out to us for advice and alternatives."
However, the family's struggle continues. Arnold's medication, originally priced at £205.50, has now skyrocketed to £312.70 per month. The oral solution, the only form Arnold can take, is typically prescribed for older children and is not funded by the States of Guernsey.
Bhogal claims no prior requests for this medication, urging clinicians to seek assistance. But for Luscombe, the reality is stark: "We're looking at £3,500 a year, and with four children, it's simply not possible."
And this is the part most people miss: reducing Arnold's dosage to stretch the medication further only made him sicker. Luscombe describes the heart-breaking scene: "His tummy swelled, he vomited, and couldn't go to the toilet. He didn't have the life he deserved."
Despite Arnold's father also suffering from a chronic illness, he had to return to work, leaving Luscombe to care for their son alone. She vows, "I've never let my children go without. We'll do whatever it takes."
The family hopes for disability allowance, but the process is lengthy. Luscombe asks, "What do we do in the meantime? Who will listen to us?"
In a powerful statement, Luscombe expresses her frustration: "I feel let down. We fight, but it seems like we keep hitting walls. No one should be denied medication because they can't afford it."
This story highlights a critical issue: the intersection of healthcare, finances, and family. It begs the question: should the cost of medication be a barrier to treatment? Join the conversation and share your thoughts in the comments.
